ESTRO 2024 - Abstract Book

S1908

Clinical - Mixed sites, palliation

ESTRO 2024

Material/Methods:

This is a retrospective multicentric study. Adult patients (≥18 years) affected by PM, treated from 2011 to 2021 with stereotactic radiotherapy for a maximum of three pleural or extrapleural sites are analyzed. SABR had to be delivered with ablative purposes (50Gy EQD2/10 delivered in a maximum of 12 fractions as per Oligocare definition). Primary endpoint is time to new systemic therapy (TTNS). Secondary endpoints are local control (LC), progression free survival (PFS), overall survival (OS), acute and late toxicity RT related.

Results:

From 5 Italian RT centers, 41 patients were enrolled in the study. Patients and treatment characteristics are shown in table 1.